Phathom Pharmaceuticals, Inc. PHAT Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s long-term debt?
- Phathom Pharmaceuticals, Inc. (PHAT) reported long-term debt of $163.68M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s long-term debt decreased by 19.5% year-over-year, from $203.25M to $163.68M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s long-term debt has grown at a 39.5% compound annual growth rate (CAGR), from $39.63M to $209.09M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.